[1]	GBD Chronic Kidney Disease Collaboration. and national burden of chronic kidney disease,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395(10225):709-733.DOI:10.1016/S0140-6736(20)30045-3. Cited in this article [1]

[2]	Wang L, Xu X, Zhang M, et al. Prevalence of chronic kidney disease in China:results from the sixth china chronic disease and risk factor surveillance[J]. JAMA Intern Med, 2023, 183(4):298-310.DOI:10.1001/jamainternmed.2022.6817. Cited in this article [1]

[3]	Chen W, Feng J, Ji P, et al. Association of hyperhomocysteinemia and chronic kidney disease in the general population:a systematic review and meta-analysis[J]. BMC Nephrol, 2023, 24(1):247.DOI:10.1186/s12882-023-03295-y. Cited in this article [2]

[4]	Wu J, Liu D, Yang L, et al. Association between serum homocysteine levels and severity of diabetic kidney disease in 489 patients with type 2 diabetes mellitus:a single-center study[J]. Med Sci Monit, 2022,28:e936323.DOI:10.12659/MSM.936323. Cited in this article [1]

[5]	Sarnak MJ, Wang SR, Beck GJ, et al. Homocysteine,cysteine,and B vitamins as predictors of kidney disease progression[J]. Am J Kidney Dis, 2002, 40(5):932-939.DOI:10.1053/ajkd.2002.36323. Cited in this article [3]

[6]	Xiao W, Ye P, Wang F, et al. Plasma homocysteine is a predictive factor for accelerated renal function decline and chronic kidney disease in a community-dwelling population[J]. Kidney Blood Press Res, 2021, 46(5):541-549.DOI:10.1159/000514360. Cited in this article [2]

[7]	Jardine MJ, Kang A, Zoungas S, et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease:systematic review and meta-analysis[J]. BMJ, 2012,344:e3533.DOI:10.1136/bmj.e3533. Cited in this article [1]

[8]	Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease:the renal substudy of the China Stroke Primary Prevention Trial[J]. JAMA Intern Med, 2016, 176(10):1443-1450.DOI:10.1001/jamainternmed.2016.4687. Cited in this article [2]

[9]	Wu DF, Yin RX, Deng JL. Homocysteine,hyperhomocysteinemia and H-type hypertension[J]. Eur J Prev Cardiol, 2024, 31(9):1092-1103.DOI:10.1093/eurjpc/zwae022. Cited in this article [2]

[10]	Skovierova H, Vidomanova E, Mahmood S, et al. The molecular and cellular effect of homocysteine metabolism imbalance on human health[J]. Int J Mol Sci, 2016, 17(10):1733.DOI:10.3390/ijms17101733. Cited in this article [1]

[11]	Stam F, van Guldener C, ter Wee PM, et al. Homocysteine clearance and methylation flux rates in health and end-stage renal disease:association with S-adenosylhomocysteine[J]. Am J Physiol Renal Physiol, 2004, 287(2):F215-F223.DOI:10.1152/ajprenal.00376.2003. Cited in this article [1]

[12]	Tessari P, Coracina A, Kiwanuka E, et al. Effects of insulin on methionine and homocysteine kinetics in type 2 diabetes with nephropathy[J]. Diabetes, 2005, 54(10):2968-2976.DOI:10.2337/diabetes.54.10.2968. Cited in this article [1]

[13]	Long Y, Nie J. Homocysteine in renal injury[J]. Kidney Dis(Basel), 2016, 2(2):80-87.DOI:10.1159/000444900. Cited in this article [3]

[14]	李建平, 卢新政, 霍勇, 等. H型高血压诊断与治疗专家共识[J]. 中华高血压杂志, 2016, 24(2):123-127.DOI:10.3969/j.issn.1674-7372.2016.05.006. Cited in this article [1]

[15]	Tu W, Yan F, Chao B, et al. Status of hyperhomocysteinemia in China:results from the China Stroke High-risk Population Screening Program,2018[J]. Front Med, 2021, 15(6):903-912.DOI:10.1007/s11684-021-0871-4. Cited in this article [1]

[16]	Shen Z, Zhang Z, Zhao W. Relationship between plasma homocysteine and chronic kidney disease in US patients with type 2 diabetes mellitus:a cross-sectional study[J]. BMC Nephrol, 2022, 23(1):419.DOI:10.1186/s12882-022-03045-6. Cited in this article [2]

[17]	Zhang H, Li Y, Hao M, et al. Kidney function decline is associated with an accelerated increase in plasma homocysteine in older adults:a longitudinal study[J]. Br J Nutr, 2022, 127(7):993-999.DOI:10.1017/S0007114521001690. Cited in this article [1]

[18]	Shi Y, Ding C, Hu L, et al. Saturation effects of plasma homocysteine on chronic kidney disease in chinese adults with H-type hypertension:a cross-sectional study[J]. J Ren Nutr, 2021, 31(5):459-466.DOI:10.1053/j.jrn.2020.09.002. Cited in this article [1]

[19]	Samuelsson O, Lee DM, Attman PO, et al. The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression[J]. Nephron, 1999, 82(4):306-311.DOI:10.1159/000045445. Cited in this article [2]

[20]	Ninomiya T, Kiyohara Y, Kubo M, et al. Hyperhomocysteinemia and the development of chronic kidney disease in a general population:the Hisayama study[J]. Am J Kidney Dis, 2004, 44(3):437-445.DOI:10.1016/s0272-6386(04)00813-3. Cited in this article [2]

[21]	Levi A, Cohen E, Levi M, et al. Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease:a historical prospective study[J]. Eur J Intern Med, 2014, 25(10):951-955.DOI:10.1016/j.ejim.2014.10.014. Cited in this article [1]

[22]	Xie D, Yuan Y, Guo J, et al. Hyperhomocysteinemia predicts renal function decline:a prospective study in hypertensive adults[J]. Sci Rep, 2015, 5:16268.DOI:10.1038/srep16268. Cited in this article [1]

[23]	Xiong Y, Zhang Y, Zhang F, et al. Genetic evidence supporting the causal role of homocysteine in chronic kidney disease:a mendelian randomization study[J]. Front Nutr, 2022,9:843534.DOI:10.3389/fnut.2022.843534. Cited in this article [1]

[24]	Menon V, Sarnak MJ, Greene T, et al. Relationship between homocysteine and mortality in chronic kidney disease[J]. Circulation, 2006, 113(12):1572-1577.DOI:10.1161/CIRCULATIONAHA.105.570127. Cited in this article [1]

[25]	Looker HC, Fagot-Campagna A, Gunter EW, et al. Homocysteine and vitamin B(12)concentrations and mortality rates in type 2 diabetes[J]. Diabetes Metab Res Rev, 2007, 23(3):193-201.DOI:10.1002/dmrr.660. Cited in this article [1]

[26]	Ding C, Li J, Wei Y, et al. Associations of total homocysteine and kidney function with all-cause and cause-specific mortality in hypertensive patients:a mediation and joint analysis[J]. Hypertens Res, 2024, 47(6):1500-1511.DOI:10.1038/s41440-024-01613-x. Cited in this article [1]

[27]

Shi W, Zhou Y, Wang H, et al. Synergistic interaction of hypertension and hyperhomocysteinemia on chronic kidney disease:findings from the National Health and Nutrition examination Survey 1999-2006[J]. J Clin Hypertens(Greenwich), 2019, 21(10):1567-1577.DOI:10.1111/jch.13673. Cited in this article [1]

[28]	Heinz J, Kropf S, Luley C, et al. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis:a meta-analysis[J]. Am J Kidney Dis, 2009, 54(3):478-489.DOI:10.1053/j.ajkd.2009.01.266. Cited in this article [1]

[29]	Cianciolo G, La Manna G, Coli L, et al. 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients[J]. Am J Nephrol, 2008, 28(6):941-948.DOI:10.1159/000142363. Cited in this article [1]

[30]	Kalantar-Zadeh K, Block G, Humphreys MH, et al. A low,rather than a high,total plasma homocysteine is an indicator of poor outcome in hemodialysis patients[J]. J Am Soc Nephrol, 2004, 15(2):442-453.DOI:10.1097/01.asn.0000107564.60018.51. Cited in this article [2]

[31]	Nair AP, Nemirovsky D, Kim M, et al. Elevated homocysteine levels in patients with end-stage renal disease[J]. Mt Sinai J Med, 2005, 72(6):365-373. Cited in this article [2]

[32]	Perna AF, Ingrosso D, Violetti E, et al. Hyperhomocysteinemia in uremia-a red flag in a disrupted circuit[J]. Semin Dial, 2009, 22(4):351-356.DOI:10.1111/j.1525-139X.2009.00579.x. Cited in this article [1]

[33]

Poddar R, Sivasubramanian N, DiBello PM, et al. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells:implications for vascular disease[J]. Circulation, 2001, 103(22):2717-2723.DOI:10.1161/01.cir.103.22.2717. Cited in this article [1]

[34]	Zeng XK, Guan YF, Remick DG, et al. Signal pathways underlying homocysteine-induced production of MCP-1 and IL-8 in cultured human whole blood[J]. Acta Pharmacol Sin, 2005, 26(1):85-91.DOI:10.1111/j.1745-7254.2005.00005.x. Cited in this article [2]

[35]	Yang J, Fang P, Yu D, et al. Chronic kidney disease induces inflammatory CD40+monocyte differentiation via homocysteine elevation and DNA hypomethylation[J]. Circ Res, 2016, 119(11):1226-1241.DOI:10.1161/CIRCRESAHA.116.308750. Cited in this article [1]

[36]	Thampi P, Stewart BW, Joseph L, et al. Dietary homocysteine promotes atherosclerosis in apoE-deficient mice by inducing scavenger receptors expression[J]. Atherosclerosis, 2008, 197(2):620-629.DOI:10.1016/j.atherosclerosis.2007.09.014. Cited in this article [1]

[37]	Zhang X, Li H, Jin H, et al. Effects of homocysteine on endothelial nitric oxide production[J]. Am J Physiol Renal Physiol, 2000, 279(4):F671-F678.DOI:10.1152/ajprenal.2000.279.4.F671. Cited in this article [1]

[38]	Steed MM, Tyagi SC. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia[J]. Antioxid Redox Signal, 2011, 15(7):1927-1943.DOI:10.1089/ars.2010.3721. Cited in this article [1]

[39]	Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine:a link to atherosclerosis[J]. Proc Natl Acad Sci USA, 1994, 91(14):6369-6373.DOI:10.1073/pnas.91.14.6369. Cited in this article [1]

[40]	Deussen A, Pexa A, Loncar R, et al. Effects of homocysteine on vascular and tissue adenosine:a stake in homocysteine pathogenicity[J]. Clin Chem Lab Med, 2005, 43(10):1007-1010.DOI:10.1515/CCLM.2005.176. Cited in this article [1]

[41]	Han L, Miao Y, Zhao Y, et al. The binding of autotaxin to integrins mediates hyperhomocysteinemia-potentiated platelet activation and thrombosis in mice and humans[J]. Blood Adv, 2022, 6(1):46-61.DOI:10.1182/bloodadvances.2021004572. Cited in this article [1]

[42]	Lei W, Liu Z, Su Z, et al. Hyperhomocysteinemia potentiates megakaryocyte differentiation and thrombopoiesis via GH-PI3K-Akt axis[J]. J Hematol Oncol, 2023, 16(1):84.DOI:10.1186/s13045-023-01481-x. Cited in this article [1]

[43]	中国营养学会骨健康与营养专业委员会, 中华医学会肠外肠内营养学分会, 中国老年医学学会北方慢性病防治分会. 高同型半胱氨酸血症诊疗专家共识[J]. 肿瘤代谢与营养电子杂志, 2020, 7(3):283-288.DOI:10.16689/j.cnki.cn11-9349/r.2020.03.007. Cited in this article [1]

[44]	Qin X, Huo Y, Xie D, et al. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease:a meta-analysis of randomized controlled trials[J]. Clin Nutr, 2013, 32(5):722-727.DOI:10.1016/j.clnu.2012.12.009. Cited in this article [2]

[45]	Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease:a randomized controlled trial[J]. JAMA, 2007, 298(10):1163-1170.DOI:10.1001/jama.298.10.1163. Cited in this article [1]

[46]	Mann JF, Sheridan P, McQueen MJ, et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease-results of the renal Hope-2 study[J]. Nephrol Dial Transplant, 2008, 23(2):645-653.DOI:10.1093/ndt/gfm485. Cited in this article [1]

[47]	Heinz J, Kropf S, Domrose U, et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease:results of a randomized controlled trial[J]. Circulation, 2010, 121(12):1432-1438.DOI:10.1161/CIRCULATIONAHA.109.904672. Cited in this article [1]

[48]	Spence JD, Yi Q, Hankey GJ. B vitamins in stroke prevention:time to reconsider[J]. Lancet Neurol, 2017, 16(9):750-760.DOI:10.1016/S1474-4422(17)30180-1. Cited in this article [2]

[49]	Li Y, Spence JD, Wang X, et al. Effect of vitamin B(12)levels on the association between folic acid treatment and CKD progression:a post hoc analysis of a folic acid interventional trial[J]. Am J Kidney Dis, 2020, 75(3):325-332.DOI:10.1053/j.ajkd.2019.07.020. Cited in this article [1]

[50]	Loscalzo J. Homocysteine trials-clear outcomes for complex reasons[J]. N Engl J Med, 2006, 354(15):1629-1632.DOI:10.1056/NEJMe068060. Cited in this article [1]

[51]	Kagawa Y, Hiraoka M, Kageyama M, et al. Medical cost savings in Sakado city and worldwide achieved by preventing disease by folic acid fortification[J]. Congenit Anom(Kyoto), 2017, 57(5):157-165.DOI:10.1111/cga.12215. Cited in this article [1]

[52]	Huang X, Qin X, Yang W, et al. MTHFR gene and serum folate interaction on serum homocysteine lowering:prospect for precision folic acid treatment[J]. Arterioscler Thromb Vasc Biol, 2018, 38(3):679-685.DOI:10.1161/ATVBAHA.117.310211. Cited in this article [1]